Liver toxicity prediction with stereotactic body radiation therapy: The impact of accounting for fraction size

• Published in: Practical radiation oncology Vol. 4; no. 6; p. 372
• Main Authors: Murphy, James D, Hattangadi-Gluth, Jona, Song, William Y, Vollans, Emily, Camborde, Marie-Laure, Kosztyla, Robert, Loewen, Shaun K, Crumley, Catherine, Moiseenko, Vitali
• Format: Journal Article
• Language: English
• Published: United States 01.11.2014
• Subjects: Dose Fractionation; Humans; Liver - pathology; Liver - radiation effects; Liver Neoplasms - pathology; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Radiation Injuries - etiology; Radiosurgery - adverse effects; Radiosurgery - methods; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted - methods; Retrospective Studies
• ISSN: 1879-8519
• DOI: 10.1016/j.prro.2013.12.004

Current liver SBRT protocols rely on the calculation of "effective volume" without accounting for the biologic effect of fraction size to estimate the risk of liver toxicity, which subsequently defines tumor prescription doses. This study compared effective volume and liver toxicity predictions with and without correction for fraction size. The effective volume was determined for 18 liver SBRT plans with and without biologic normalization using the linear quadratic formula. Lyman-Kutcher-Burman normal tissue complication probability models estimated the risk of liver toxicity. Effective volumes and corresponding toxicity predictions were compared with and without biologic normalization. Accounting for the biologic difference of larger fraction size reduced the effective volume in all treatment plans compared with the unadjusted effective volume (median effective volume 0.21 vs 0.32). The lower effective volume with biologic normalization substantially reduced the estimated risk of liver toxicity (average risk of toxicity 32% vs 4.5%). This study demonstrates that accounting for the biologic effect of fraction size with effective volume significantly decreases predicted hepatic toxicity, which suggests that the risk of liver toxicity may be overestimated in clinical practice if biologic normalization is omitted. The effective volume toxicity model has proven safe in prospective clinical trials, though safe dose escalation with liver SBRT may be feasible.